{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:26:40Z","timestamp":1740166000806,"version":"3.37.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes in Taiwan","doi-asserted-by":"crossref","award":["CA-108-PP-28"],"award-info":[{"award-number":["CA-108-PP-28"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>New-generation breakpoint cluster region-Abelson tyrosine kinase inhibitors (TKIs) have a higher incidence of cardiovascular events than imatinib in patients with chronic myeloid leukaemia (CML). However, this knowledge is insufficiently proven. Hence, this study aimed to explore the association between cardiovascular events and TKIs in patients with CML.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This retrospective population-based cohort study enrolled first-time users of imatinib, dasatinib, and nilotinib between 1 January 2007 and 31 December 2016. Arterial thromboembolic events (ATEs) were the primary outcome, while other cardiovascular-related events were the secondary outcomes. The event rates were estimated using Kaplan\u2013Meier estimates, and the hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression. Additionally, the competing risk was adjusted using the Fine and Gray competing risk model. We included 1207 patients. Nilotinib had a significantly higher ATE risk (subdistribution HR = 4.92, 95% CI = 1.68\u201314.36) than imatinib. Conversely, no difference was found for other cardiovascular-related events. Risks of ATE and other cardiovascular-related events were similar between dasatinib and imatinib and between nilotinib and dasatinib. The risk of ATE hospitalization consistently increased throughout the main analyses and sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Nilotinib-treated patients had a significantly higher risk of developing ATE than imatinib-treated patients. However, the risks of ATE and other cardiovascular-related events were not significantly different between dasatinib and imatinib.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwab043","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T20:09:30Z","timestamp":1615061370000},"page":"1312-1321","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study"],"prefix":"10.1093","volume":"29","author":[{"given":"Yu Chien","family":"Yang","sequence":"first","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Kaohsiung Medical University , No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung City 80708 , Taiwan"},{"name":"Department of Pharmacy, E-Da Hospital , No. 1, Yida Rd., Yanchao Dist., Kaohsiung City 824005 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"National Institute of Cancer Research, National Health Research Institutes , No. 367, Sheng-Li Road, North District, Tainan 70456 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Jen","family":"Tsai","sequence":"additional","affiliation":[{"name":"National Institute of Cancer Research, National Health Research Institutes , No. 367, Sheng-Li Road, North District, Tainan 70456 , Taiwan"},{"name":"Department of Internal Medicine, Kaohsiung Medical University Hospital , No. 100, Tzyou 1st Rd., Sanmin District, Kaohsiung City 80756 , Taiwan"},{"name":"Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , No. 138, Sheng-Li Road, North District, Tainan 70456 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po Chih","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Kaohsiung Medical University , No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung City 80708 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Hsin","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Kaohsiung Medical University , No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung City 80708 , Taiwan"},{"name":"National Institute of Cancer Research, National Health Research Institutes , No. 367, Sheng-Li Road, North District, Tainan 70456 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-2936","authenticated-orcid":false,"given":"Kun Pin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"School of Pharmacy, College of Pharmacy, Kaohsiung Medical University , No. 100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung City 80708 , Taiwan"},{"name":"Department of Pharmacy, Kaohsiung Medical University Hospital , No. 100, Tzyou 1st Rd., Sanmin District, Kaohsiung City 80756 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"2022072021484785100_zwab043-B1","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/s00277-015-2331-1","article-title":"CML\u2014where do we stand in 2015?","volume":"94","author":"Hehlmann","year":"2015","journal-title":"Ann Hematol"},{"key":"2022072021484785100_zwab043-B2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3324\/haematol.2016.142877","article-title":"Innovation in hematology. Perspectives: CML 2016","volume":"101","author":"Hehlmann","year":"2016","journal-title":"Haematologica"},{"key":"2022072021484785100_zwab043-B3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"2022072021484785100_zwab043-B4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022072021484785100_zwab043-B5","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","article-title":"Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database","volume":"97","author":"Fujioka","year":"2018","journal-title":"Ann Hematol"},{"key":"2022072021484785100_zwab043-B6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022072021484785100_zwab043-B7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022072021484785100_zwab043-B8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022072021484785100_zwab043-B9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2022072021484785100_zwab043-B10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's National Health Insurance Research Database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2022072021484785100_zwab043-B11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","article-title":"Taiwan's Nationwide Cancer Registry System of 40 years: past, present, and future","volume":"118","author":"Chiang","year":"2019","journal-title":"J Formos Med Assoc"},{"volume-title":"Disease Staging: Coded Criteria V.5.24","year":"2007","author":"Gonnella","key":"2022072021484785100_zwab043-B12"},{"key":"2022072021484785100_zwab043-B13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1472-6963-12-359","article-title":"Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis","volume":"12","author":"Chang","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"2022072021484785100_zwab043-B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2022072021484785100_zwab043-B15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ndt\/gfq661","article-title":"The analysis of competing events like cause-specific mortality\u2014beware of the Kaplan-Meier method","volume":"26","author":"Verduijn","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2022072021484785100_zwab043-B16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2022072021484785100_zwab043-B17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.mayocp.2019.03.001","article-title":"Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study","volume":"94","author":"Su","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2022072021484785100_zwab043-B18","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022072021484785100_zwab043-B19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"2022072021484785100_zwab043-B20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2022072021484785100_zwab043-B21","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"key":"2022072021484785100_zwab043-B22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers"},{"key":"2022072021484785100_zwab043-B23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood.V126.23.1593.1593","article-title":"Safety and efficacy of nilotinib (NIL) in patients (PTS) with chronic phase (CP) or accelerated phase (AP) philadelphia chromosome positive (ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib mesylate (IM): results from the multicenter, observational novel study in Taiwan","volume":"126","author":"Kuo","year":"2015","journal-title":"Blood"},{"key":"2022072021484785100_zwab043-B24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"2022072021484785100_zwab043-B25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb Res"},{"key":"2022072021484785100_zwab043-B26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"2022072021484785100_zwab043-B27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40959-015-0008-5","article-title":"Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia","volume":"1","author":"Pasvolsky","year":"2015","journal-title":"Cardio-Oncology"},{"key":"2022072021484785100_zwab043-B28","first-page":"239","article-title":"Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: a case report","volume":"10","author":"Suzuki","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2022072021484785100_zwab043-B29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cancers12051242","article-title":"Long-term survival, vascular occlusive events and efficacy biomarkers of first-line treatment of CML: a meta-analysis","volume":"12","author":"Haguet","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2022072021484785100_zwab043-B30","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/cpt.1722","article-title":"Association of statin and its lipophilicity with cardiovascular events in patients receiving chronic dialysis","volume":"107","author":"Wang","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2022072021484785100_zwab043-B31","article-title":"The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology","author":"D\u2019Ascenzi","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2022072021484785100_zwab043-B32","article-title":"Cardiorespiratory fitness and cancer in men with cardiovascular disease: analysis from the Veterans Exercise Testing Study","author":"Vainshelboim","year":"2020","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/9\/1312\/45032538\/zwab043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/9\/1312\/45032538\/zwab043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T21:49:56Z","timestamp":1658353796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/29\/9\/1312\/6310291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2022,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwab043","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"type":"print","value":"2047-4873"},{"type":"electronic","value":"2047-4881"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,6,28]]}}}